Atlas Trials

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Clinical trial NCT03452579 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03452579
Sponsor
David Peereboom
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Glioblastoma
Start date
2018-05-21
Primary completion
2020-12-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.